— Know what they know.
Not Investment Advice
Also trades as: ORXOY (OTC) · $vol 0M

ORXOF OTC

Orexo AB (publ)
1W: +0.0% 1M: +0.0% 3M: -31.4% YTD: -55.4% 1Y: -43.5% 3Y: -44.2% 5Y: -81.3%
$1.44
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Strong Sell · Power 41 · $50.6M mcap · 17M float · 0.0007% daily turnover · Short 100% of daily vol

Cash Flow Trends

Operating Cash Flow
$173M +629.3% ▲
5Y CAGR: +59.3%
Capital Expenditures
$0 +100.0% ▲
Free Cash Flow
$173M +563.9% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$808M +1793.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$214M-$184M-$128M-$140M-$402M
Depreciation & Amort.$53M$69M$77M$189M$67M
Stock-Based Comp.$2M-$100K$0$0$0
Change in Working Capital$17M$50M-$54M-$2M$56M
Other Non-Cash Items-$86M-$92M$10M-$79M$452M
Operating Cash Flow-$229M-$157M-$95M-$33M$173M
— Investing Activities —
Capital Expenditures-$53M-$24M-$18M-$3M$0
Acquisitions (Net)$0$800K$0$0$0
Investment Purchases$0-$296M$0-$700K-$19M
Investment Sales$0$84M$220M$0$0
Other Investing-$100K-$216M-$700K-$2M$653M
Investing Cash Flow-$53M-$235M$201M-$5M$634M
— Financing Activities —
Net Debt Issuance$251M$0-$49M$6M$20M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0-$21M-$21M-$22M-$22M
Financing Cash Flow$251M-$21M-$70M-$16M-$2M
Net Change in Cash-$1M-$372M$39M-$48M$808M
Cash End of Period$504M$132M$171M$123M$910M
Free Cash Flow-$282M-$180M-$114M-$37M$173M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms